Technology | June 16, 2015

Apple Introduces ResearchKit Mobile Platform

Open software framework gives medical researchers the tools to improve collection of medical research data

Apple, ResearchKit, open software research, medical research apps

June 16, 2015 - In March, Apple announced the launch of ResearchKit, an open source software framework designed for medical and health research. The platform is designed to help doctors and scientists gather data more frequently and more accurately from participants using iPhone apps. World-class research institutions have already developed apps with ResearchKit for studies on asthma, breast cancer, cardiovascular disease, diabetes and Parkinson's disease. Users decide if they want to participate in a study and how their data is shared.

ResearchKit turns iPhone into a powerful tool for medical research. When granted permission by the user, apps can access data from the Health app such as weight, blood pressure, glucose levels and asthma inhaler use, which are measured by third-party devices and apps. HealthKit is a software framework Apple introduced with iOS 8 to provide developers the ability for health and fitness apps to communicate with each other. ResearchKit can also request access to the accelerometer, microphone, gyroscope and GPS sensors in iPhone to gain insight into a patient's gait, motor impairment, fitness, speech and memory.

ResearchKit also makes it easier to recruit participants for large-scale studies, accessing a broad cross-section of the population - not just those within driving distance of an institution. Study participants can complete tasks or submit surveys right from the app, so researchers spend less time on paperwork and more time analyzing data. ResearchKit also enables researchers to present an interactive informed consent process. Users choose which studies to participate in and the data they want to provide in each study.

"We're excited to use these new ResearchKit tools from Apple to expand participant recruitment and quickly gather even more data through the simple use of an iPhone app. The data it will provide takes us one step closer to developing more personalized care," said Patricia Ganz, M.D., professor at the UCLA Fielding School of Public Health and director of cancer prevention & control research at UCLA's Jonsson Comprehensive Cancer Center. "Access to more diverse patient-reported health data will help us learn more about long-term aftereffects of cancer treatments and provide us with a better understanding of the breast cancer patient experience."

"When it comes to researching how we can better diagnose and prevent disease, numbers are everything. By using Apple's new ResearchKit framework, we're able to extend participation beyond our local community and capture significantly more data to help us understand how asthma works," said Eric Schadt, Ph.D., the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai, and founding director of the Icahn Institute for Genomics and Multiscale Biology. "Using iPhone's advanced sensors, we're able to better model an asthma patient's condition to enable us to deliver a more personalized, more precise treatment."

Developed by the Icahn School of Medicine at Mount Sinai and LifeMap Solutions, the Asthma Health app is designed to facilitate asthma patient education and self-monitoring, promote positive behavioral changes and reinforce adherence to treatment plans according to current asthma guidelines. The study tracks symptom patterns in an individual and potential triggers for these exacerbations so that researchers can learn new ways to personalize asthma treatment.

Other health apps already designed include:

  • The Share the Journey app, developed by the Dana-Farber Cancer Institute, Penn Medicine, Sage Bionetworks and UCLA's Jonsson Comprehensive Cancer Center, is a research study that aims to understand why some breast cancer survivors recover faster than others, why their symptoms vary over time and what can be done to improve symptoms. Share the Journey uses surveys and sensor data on iPhone to collect and track fatigue, mood and cognitive changes, sleep disturbances and reduction in exercise.
  • Developed by Stanford Medicine, the MyHeart Counts app measures activity and uses risk factor and survey information to help researchers more accurately evaluate how a participant's activity and lifestyle relate to cardiovascular health. By studying these relationships on a broad scale, researchers will be able to understand better how to keep hearts healthier.
  • Massachusetts General Hospital developed the GlucoSuccess app to understand how various aspects of a person's life - diet, physical activity and medications - affect blood glucose levels. The app can also help participants identify how their food choices and activity relate to their best glucose levels, enabling them to clearly see correlations and take more active roles in their own well-being.
  • Developed by Sage Bionetworks and the University of Rochester, the Parkinson mPower app helps people living with Parkinson's disease track their symptoms by recording activities using sensors in iPhone. These activities include a memory game, finger tapping, speaking and walking. Activity and survey data from the phone are combined with data from many other participants to fuel Parkinson's research at a scale never before possible, making it the world's largest and most comprehensive study of this disease.

 

ResearchKit was released as an open source framework in April, providing researchers with the ability to contribute to specific activity modules in the framework, like memory or gait testing, and share them with the global research community to further advance what we know about disease.

ResearchKit apps are available on the App Store.

 

For more information: www.apple.com/researchkit

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init